Nyhetsarkiv

25 Maj 2021 00:00

New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine

25 Maj 2021 00:00

OnDosis completes a private placement of SEK 92 million led by Aeternum Capital

OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.

10 Februari 2021 15:46

New business partner and international recognition for OnDosis

OnDosis wants to revolutionize the way we take our medicines. The idea is that every single patient, in the easiest possible way, shall get precisely the right amount of medicine and thus lead a better life. Now the company begins a cooperation with Opatus, whose digital tool objectively scales symptoms of ADHD patients. In addition, OnDosis recently received a double recognition at the large

11 September 2020 00:00

OnDosis announces commitment of 30 MSEK raise from existing owners and DIG Investment

Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment

10 September 2020 00:00

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent do

15 November 2019 00:00

OnDosis featured in IPI Magazine

Pharmaceutical innovation is accelerating fast, but the way of dosing oral medicines to patients has very much stayed the same. This article in IPI magazine, “Beyond the Pill Personalisation by Integrating Oral Medication and Digitalisation”, highlights the opportunities with OnDosis.

29 Januari 2019 00:00

Breakthrough for OnDosis

License option agreement with leading global pain company